Ustekinumab biosimilar is under clinical development by Alvotech and currently in Pre-Registration for Plaque Psoriasis (Psoriasis Vulgaris). According to GlobalData, Pre-Registration drugs for Plaque Psoriasis (Psoriasis Vulgaris) have a 90% phase transition success rate (PTSR) indication benchmark for progressing into Marketed. GlobalData’s report assesses how Ustekinumab biosimilar’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
Ustekinumab biosimilar overview
ustekinumab biosimilar is under development for the treatment of crohn disease plaque psoriasis, psoriatic arthritis and ulcerative colitis. The drug candidate is a biosimilar developed based on Smart Factory GMP manufacturing technology. It is administered through subcutaneous route. The drug candidate acts by targeting interleukin 12 subunit beta and interleukin 23 subunit alpha.
Alvotech is a biopharmaceutical company that focused on development and manufacturing of biosimilar medicines. The company’s purpose is to improve the health and quality of life of patients by improving access to proven treatments for various diseases. Its current pipeline contains eight biosimilar candidates for the treatment of autoimmune disorders, eye disorders, osteoporosis, respiratory disease, and cancer, among others. It also offer research and development services. Alvotech work in partnerships and collaborations with other pharmaceutical companies and research universities which offering manufacturing, regulatory management and license agreements for its biosimilar assets. It has operations in Luxemburg, Switzerland, Germany and Iceland. Alvotech is headquartered in Luxemburg.
For a complete picture of Ustekinumab biosimilar’s drug-specific PTSR and LoA scores, buy the report here.